Estimands in practice: Bridging the gap between study objectives and statistical analysis.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 68, doi. 10.1002/pst.2056
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2021 AND VI 20 AND IP 1
Results: 17
1
2
Cancer immunotherapy trial design with long‐term survivors.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 117, doi. 10.1002/pst.2060
- By:
- Publication type:
- Article
3
A method for sample size calculation via E‐value in the planning of observational studies.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 163, doi. 10.1002/pst.2064
- By:
- Publication type:
- Article
4
Evaluation of alternative confidence intervals to address non‐inferiority through the stratified difference between proportions.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 146, doi. 10.1002/pst.2063
- By:
- Publication type:
- Article
5
Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 129, doi. 10.1002/pst.2062
- By:
- Publication type:
- Article
6
Assessing the quality of studies in meta‐research: Review/guidelines on the most important quality assessment tools.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 185, doi. 10.1002/pst.2068
- By:
- Publication type:
- Article
7
Use of a two‐sided tolerance interval in the design and evaluation of biosimilarity in clinical studies.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 175, doi. 10.1002/pst.2065
- By:
- Publication type:
- Article
8
Controlling type I error rates in multi‐arm clinical trials: A case for the false discovery rate.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 109, doi. 10.1002/pst.2059
- By:
- Publication type:
- Article
9
An application of the mixed‐effects model and pattern mixture model to treatment groups with differential missingness suspected not‐missing‐at‐random.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 93, doi. 10.1002/pst.2058
- By:
- Publication type:
- Article
10
Recurrent time‐to‐event models with ordinal outcomes.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 77, doi. 10.1002/pst.2057
- By:
- Publication type:
- Article
11
Comments on "Incorporating historical two‐arm data in clinical trials with binary outcome: A practical approach" by Manuel Feißt, Johannes Krisam and Meinhard Kieser.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 196, doi. 10.1002/pst.2061
- By:
- Publication type:
- Article
12
Prior distributions for variance parameters in a sparse‐event meta‐analysis of a few small trials.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 39, doi. 10.1002/pst.2053
- By:
- Publication type:
- Article
13
Augmented inverse probability weighted fractional imputation in quantile regression.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 25, doi. 10.1002/pst.2052
- By:
- Publication type:
- Article
14
To use or not to use propensity score matching?
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 15, doi. 10.1002/pst.2051
- By:
- Publication type:
- Article
15
Designing historical control studies with survival endpoints using exact statistical inference.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 4, doi. 10.1002/pst.2050
- By:
- Publication type:
- Article
16
Implementation of tripartite estimands using adherence causal estimators under the causal inference framework.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 55, doi. 10.1002/pst.2054
- By:
- Publication type:
- Article
17
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2021, v. 20, n. 1, p. 1, doi. 10.1002/pst.2033
- Publication type:
- Article